Let’s face it, drug developers could use the efficiency that mobile apps promise. With many big market opportunities across the life sciences industry, many companies have either developed smartphone- or tablet-compatible software versions or have launched and promoted their own dedicated mobile applications. In this slideshow, we feature 10 apps that have been released or updated within the past two years. Among these apps are Veeva’s iRep app for use by pharmaceutical sales reps, PPD’s clinical trials mobile app and PHT’s SmartReports Mobile. This isn’t meant to be a definitive list of all the best mobile apps in life sciences, but we feel that these are worth a look.
Gene therapy boost in mice blocked HIV virus Read more: Gene therapy boost in mice blocked HIV virus
Researchers at the California Institute of Technology and elsewhere may have found a way to prevent HIV. They used a form of gene therapy to successfully block mice from contracting the deadly virus, The Huffington Post is reporting.
AVEO Pharmaceuticals and Boehringer Ingelheim have entered into an agreement for large-scale process development and clinical manufacturing of ficlatuzumab, AVEO’s HGF inhibitory antibody currently in Phase II development in non-small cell lung cancer (NSCLC). Boehringer will produce ficlatuzumab for clinical trials at its biopharmaceutical site in Fremont, CA. AVEO retains all rights to develop and commercialize ficlatuzumab. Financial terms were not disclosed.
The Scripps Research Institute has developed a new class of small molecules which are believed to have the potential to serve as a foundation for drug discovery. The new approach combines synthetic chemistry with advanced screening technologies which would expand the number of provocative synthetic compounds available to explore as potential drug candidates.
The Leukemia & Lymphoma Society (LLS) has pledged up to $4 million in funding to support continued development of Curis’ B-cell lymphoma and multiple myeloma candidate CUDC-907. The oral small molecule dual PI3K and HDAC inhibitor is currently in preclinical development, and clinical trials are projected to start in the second half of 2012.
Geoffrey Porges and his team of analysts at Sanford C. Bernstein took another look at the patent Amgen was issued last week on the top-selling drug Enbrel, used to treat rheumatoid arthritis, psoriasis, and other immune diseases. They found that the patent was more valuable than it initially appeared, because it would allow the biotechnology [...]
Today, the U.S. patent expires on the Pfizer’s Lipitor, the best-selling drug of all time. The first generic versions will go for sale, marking the end of a brand that has dominated the drug industry, lowered the cholesterol of tens of millions of patients, and generated more in annual sales than Major League Baseball or the entire box office of U.S. movies.
Addex Scientists Discover Glucagon-like-peptide-1 (GLP-1) Induced Interaction Between GLP-1 and Gastric Inhibitory Peptide (GIP) Read more: Addex Scientists Discover Glucagon-like-peptide-1 (GLP-1) Induced Interaction Between GLP-1 and Gastric Inhibitory Peptide (GIP)
Addex Pharmaceuticals / Addex Scientists Discover Glucagon-like-peptide-1 (GLP-1) Induced Interaction Between GLP-1 and Gastric Inhibitory Peptide (GIP) Receptors . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement.
We anticipate that shares of Arena Pharmaceuticals (ARNA) will continue to creep up after Analysts at Piper Jaffray have upgraded the firm and raised the share price target from $1.50 to $3. The Piper analyst says the company has made substantial progress addressing the FDA’s requests in its Complete Response Letter, and rectified all the necessary issues to meet the final requirements for a New Drug Application re-submission involving Lorcaserin Hydrochloride for the treatment of Obesity. Back in October of 2010, U.S. Food and Drug Administration officials issued the Complete Response Letter.
Roche is paying PTC Therapeutics $30 million up front for an exclusive, worldwide license to the latter’s spinal muscular atrophy (SMA) program. It includes three preclinical-stage candidates and potential back-up programs. PTC has been developing the program in partnership wtih the SMA Foundation, which will retain an active role in the collaboration. The deal with Roche could see PTC receive up to $460 million in development and commercialization milestones plus potentially double-digit royalties on commercial sales.